Navigation Links
Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord

Projects have vast potential to help scientists worldwide gain new insight

into neurological diseases and disorders Institute seeks funding support for human brain, spinal cord and developing

brain projects

SEATTLE, March 13 /PRNewswire/ -- The Allen Institute for Brain Science announced today that it is undertaking three major projects designed to accelerate brain, and spinal cord research, and help scientists worldwide gain new insight into numerous diseases and disorders.

The Institute will create three new Web-based atlas resources that map gene activity in the brain and spinal cord. These include an atlas designed to provide insight into gene expression in the human brain; an atlas of the developing mouse brain designed to illustrate and enhance understanding of gene activity across multiple stages of development from birth through adulthood; and an atlas of the mouse spinal cord designed to inform research into spinal injuries due to disease, disorder or trauma.

The new atlases will be officially known as the Allen Brain Atlas (ABA)- Human Brain, ABA-Developing Mouse Brain, and ABA-Mouse Spinal Cord. Upon completion, the atlases will be made publicly available on the Internet at no charge to users to encourage widespread use and scientific collaboration.

"Building on the success of our inaugural Allen Brain Atlas project, we are inspired to take on projects at the leading edge of science -- creating large-scale resources that will fuel innovation for countless discoveries in brain research," said Allan Jones, Chief Scientific Officer at the Allen Institute. "Scientists in the research community agree that these projects will provide a transformative catalyst for advancing and promoting innovation, ultimately allowing for the most positive impact worldwide. The Institute is uniquely suited to successfully complete these projects because of its established technology platforms and multidisciplinary reach."

Recognizing that the atlases can exponentially advance the global understanding of many diseases and disorders that afflict millions, the Allen Institute has been successful in bringing diverse groups together to fund a common project by providing centralized databases of information that an individual researcher might spend a lifetime trying to gather.

"By putting our data in the hands of scientists studying devastating diseases and disorders such as autism, obesity, epilepsy, schizophrenia and Amyotrophic Lateral Sclerosis (ALS), these new projects will enable the work of many researchers, industries and organizations," said Elaine Jones, Chief Operating Officer at the Allen Institute. "We believe that free access to our unique resources is the best way to encourage widespread use and collaboration, which ultimately could expedite progress toward life-changing medical breakthroughs."

Mapping the Human Brain

Building on new technology and information gained in the development of its inaugural project, the ABA-Mouse Brain, which was completed in 2006, the Institute will develop the ABA-Human Brain, the world's first human brain atlas that overlays information about gene activity onto a three-dimensional anatomic map. For the first time and using a fresh approach to human brain mapping, the Institute will create a unique resource for understanding genes at work in the human brain and combining information about gene activity with existing anatomic and functional knowledge.

Currently, about 26 percent of American adults -- close to 58 million people -- suffer from a diagnosable mental disorder in a given year. This atlas will enable researchers and clinicians worldwide to advance understanding of brain diseases and disorders and speed progress toward breakthrough therapies.

"Ultimately, understanding the anatomic basis of gene expression in the normal brain will enable us to more effectively target abnormal gene expression in individual patients with brain cancer," said Dr. Greg Foltz, a neurosurgeon at Swedish Medical Center in Seattle, Wash. "As we move into the new era of personalized medicine, understanding the variability between individuals with highly heterogeneous diseases will be fundamental to developing effective treatment strategies. The human brain atlas will provide a critical resource for any scientist or physician interested in treating diseases of the brain."

When completed in approximately four years, the ABA-Human Brain will provide the scientific community with a comprehensive map of gene activity in the human brain. The key features include a quantitative inventory of which genes are turned on in each brain structure and a finer-resolution image database pinpointing to the cellular level where a selected list of high-value genes are turned on.

Understanding the Developing Brain

The ABA-Developing Mouse Brain will provide new insights into how a brain develops and matures. For this two-year project, the Institute will develop a highly detailed map of gene activity in the developing mouse brain. The resulting atlas will comprise an extensive image database showing where several thousand genes are expressed, or "turned on," in the mouse brain at multiple stages of development, from before birth through adulthood. In addition, it will show gene expression in various organs within the embryo.

"The developing brain atlas provides a molecular narrative of how the genetic map of the brain unfolds in space and time," said Dr. David Anderson, professor of biology and Howard Hughes Medical Institute investigator at the California Institute of Technology. "The atlas will be invaluable in gaining insight into the origins of certain behavioral disorders, such as schizophrenia and autism, which are increasingly thought to result from abnormalities of brain development."

This new atlas holds promise for furthering understanding of human developmental disorders such as autism and other age-associated conditions including schizophrenia and Alzheimer's disease. In addition, it is likely to uncover new opportunities for therapeutic intervention, as genes that are important for healthy brain development and maintenance may be helpful in slowing progress of degenerative diseases, preventing life-changing secondary brain damage from stroke or other brain injuries and repairing brain tissue already damaged by injury or disease.

Analyzing the Spinal Cord

In response to specific requests from the spinal cord research community and advocacy groups, and with support from a diverse consortium of funders, the Institute is following its successful ABA-Mouse Brain project with an atlas mapping gene expression in the mouse spinal cord. Expected to be complete in a one-year timeframe, the ABA-Spinal Cord will be a comprehensive genome-wide survey of gene expression that pinpoints where each gene is expressed -- or "turned on" -- in both juvenile and adult mouse spinal cord.

"The spinal cord is relatively small, compared to the brain, but it is a crucial highway for transmitting signals between the brain and the rest of the body in order to make everything work the way we need it to," said Dr. Jane Roskams, associate professor at the Brain Research Center and iCord at the University of British Columbia. "It may be small, but can be catastrophic when it becomes broken. The problem is that we know very little about the genes that control different functions in the spinal cord. This mouse spinal cord atlas will absolutely help researchers advance their work in this area in quantum leaps, and maybe it will help us discover how to make spinal cord patients take leaps of their own."

The Institute hopes this unique database will support the entire spinal cord research community, offering an essential baseline of the normal mouse spinal cord for comparison with models of injuries or diseases found in humans. The atlas holds great promise for furthering understanding of diseases and disorders affecting the spinal cord -- including ALS, multiple sclerosis, Spinal Muscular Atrophy and spinal cord injuries -- and pointing the way for effective treatments.

The ABA-Spinal Cord is funded by a group of disease organizations, foundations, and corporate and private donors. The Institute will continue seeking support from individuals and organizations for the spinal cord atlas project.

"We are excited to see such a diverse array of funders come forward with the shared goal of supporting this project to advance spinal cord research," said Elaine Jones. "This is an example of individuals and organizations coming together to fund an important project that will empower scientists and have far-reaching impacts on spinal cord research in the future. We look forward to building similar funding groups for our human brain atlas, developing brain atlas and other projects moving forward."

About the Allen Institute for Brain Science

Launched in 2003, the Seattle-based Allen Institute for Brain Science is an independent, 501(c)(3) non-profit medical research organization dedicated to advancing brain research. Started with $100 million in seed money from philanthropist Paul G. Allen, the Institute takes on projects at the leading edge of science-far-reaching projects at the intersection of biology and technology. The resulting data create publicly available resources that fuel discovery for countless other researchers worldwide. The Institute's data and tools are available on the Web free of charge at

Media Contact: Aaron Blank, The Fearey Group for the Allen Institute for

Brain Science

(206) 343-1543 or

SOURCE Allen Institute for Brain Science
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers
6. Triage study challenges notions of emergency medical response to disaster
7. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
8. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
9. Beyond DTC: Pharma Industry Faces New Challenges, Competition, Strategies for Market Dominance
10. White Paper Details Infection Control Challenges Hospitals Must Address During Construction
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Disappearing forests ... the lives of over 5.5 million people each year. Especially those living in larger ... startup Treepex - based in one of the most pollution-affected countries globally - decided ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at . 2016 Year Highlights: ...
Breaking Biology News(10 mins):